Cargando…

Assessment of POLE and POLD1 mutations as prognosis and immunotherapy biomarkers for stomach adenocarcinoma

BACKGROUND: Cancer patients with POLE or POLD1 mutations may be excellent candidates for immune checkpoint inhibitors (ICIs) therapy and have favorable prognosis, but their potential in stomach adenocarcinoma (STAD) remains unknown. Therefore, the clinical significance of POLE and POLD1 mutations in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Mingyu, Cui, Haiyan, Zhang, Lu, Zhao, Kuo, Jia, Xiaochen, Jin, Hao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841685/ https://www.ncbi.nlm.nih.gov/pubmed/35261896 http://dx.doi.org/10.21037/tcr-21-1601

Ejemplares similares

POLE/POLD1 mutation and tumor immunotherapy
por: Ma, Xiaoting, et al.
Publicado: (2022)

Role of POLE and POLD1 in familial cancer
por: Mur, Pilar, et al.
Publicado: (2020)

Risk of colorectal cancer for carriers of a germline mutation in POLE or POLD1
por: Buchanan, Daniel D., et al.
Publicado: (2017)

Integrating POLE / POLD1 mutated for immunotherapy treatment planning of advanced stage non‐small cell lung cancer
por: Zheng, Shuhua, et al.
Publicado: (2023)

Germline mutations in the proof-reading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas
por: Palles, Claire, et al.
Publicado: (2012)

Recommendations for the classification of germline variants in the exonuclease domain of POLE and POLD1
por: Mur, Pilar, et al.
Publicado: (2023)

POLE/POLD1 mutation in non‐exonuclease domain matters for predicting efficacy of immune‐checkpoint‐inhibitor therapy
por: Chen, Yan‐Xing, et al.
Publicado: (2021)

Germline POLE and POLD1 proofreading domain mutations in endometrial carcinoma from Middle Eastern region
por: Siraj, Abdul K., et al.
Publicado: (2019)

Detection of Allelic Variants of The POLE and POLD1 Genes in Colorectal Cancer Patients
por: Pätzold, LA, et al.
Publicado: (2017)

POLE and POLD1 pathogenic variants in the proofreading domain in papillary thyroid cancer
por: Siraj, Abdul K, et al.
Publicado: (2020)

Comprehensive analysis of POLE and POLD1 Gene Variations identifies cancer patients potentially benefit from immunotherapy in Chinese population
por: Yao, Jianfei, et al.
Publicado: (2019)

Low frequency of POLD1 and POLE exonuclease domain variants in patients with multiple colorectal polyps
por: Elsayed, Fadwa A., et al.
Publicado: (2019)

POLE and POLD1 screening in 155 patients with multiple polyps and early-onset colorectal cancer
por: Esteban-Jurado, Clara, et al.
Publicado: (2017)

Roles of human POLD1 and POLD3 in genome stability
por: Tumini, Emanuela, et al.
Publicado: (2016)

Combined mismatch repair and POLE/POLD1 defects explain unresolved suspected Lynch syndrome cancers
por: Jansen, Anne ML, et al.
Publicado: (2016)

POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance
por: Bellido, Fernando, et al.
Publicado: (2016)

Identification of miRNA biomarkers for stomach adenocarcinoma
por: Qian, Hao, et al.
Publicado: (2022)

Two Similar Signatures for Predicting the Prognosis and Immunotherapy Efficacy of Stomach Adenocarcinoma Patients
por: Yue, Taohua, et al.
Publicado: (2021)

Rare germline variants in POLE and POLD1 encoding the catalytic subunits of DNA polymerases ε and δ in glioma families
por: Weber, Christine A. M., et al.
Publicado: (2023)

Somatic Mutation of FAT Family Genes Implicated Superior Prognosis in Patients With Stomach Adenocarcinoma
por: Wang, Qingjun, et al.
Publicado: (2022)

Elevated expression of POLD1 is associated with poor prognosis in breast cancer
por: Qin, Qinghong, et al.
Publicado: (2018)

Novel mutations and phenotypic associations identified through APC, MUTYH, NTHL1, POLD1, POLE gene analysis in Indian Familial Adenomatous Polyposis cohort
por: Khan, Nikhat, et al.
Publicado: (2017)

Identification of mitochondrial respiratory chain signature for predicting prognosis and immunotherapy response in stomach adenocarcinoma
por: Yang, Jing, et al.
Publicado: (2023)

POLE and POLD1 germline exonuclease domain pathogenic variants, a rare event in colorectal cancer from the Middle East
por: Siraj, Abdul K., et al.
Publicado: (2020)

GPR176 Is a Biomarker for Predicting Prognosis and Immune Infiltration in Stomach Adenocarcinoma
por: Ni, Lin, et al.
Publicado: (2023)

Co-Mutation of FAT3 and LRP1B in Lung Adenocarcinoma Defines a Unique Subset Correlated With the Efficacy of Immunotherapy
por: Zhu, Mingyu, et al.
Publicado: (2022)

Non-Exonuclease Domain POLE Mutations Associated with Immunotherapy Benefit
por: Dong, Sharlene, et al.
Publicado: (2022)

Identification of a Metabolic Reprogramming-Associated Risk Model Related to Prognosis, Immune Microenvironment, and Immunotherapy of Stomach Adenocarcinoma
por: Zhao, Yan, et al.
Publicado: (2022)

Distinctive genomic characteristics in POLE/POLD1-mutant cancers can potentially predict beneficial clinical outcomes in patients who receive immune checkpoint inhibitor
por: He, Junjun, et al.
Publicado: (2021)

The Value of m5C-Related lncRNAs in the Prognostic Assessment and Immunotherapy of Stomach Adenocarcinoma
por: He, Chenxi, et al.
Publicado: (2022)

POLE proofreading mutation, immune response and prognosis in endometrial cancer
por: van Gool, Inge C., et al.
Publicado: (2015)

CTCF Mediates Replicative Senescence Through POLD1
por: Hou, Yuli, et al.
Publicado: (2021)

Prospects of POLD1 in Human Cancers: A Review
por: Gola, Michał, et al.
Publicado: (2023)

PARP1 and POLD2 as prognostic biomarkers for multiple myeloma in autologous stem cell transplant
por: Thomas, Melissa, et al.
Publicado: (2023)

Identification of Early Diagnostic and Prognostic Biomarkers via WGCNA in Stomach Adenocarcinoma
por: Tan, Ruoyue, et al.
Publicado: (2021)

The circadian clock is associated with prognosis and immune infiltration in stomach adenocarcinoma
por: Huang, Zhihao, et al.
Publicado: (2021)

GGT5 Is an Independent Prognostic Biomarker in Stomach Adenocarcinoma
por: Huang, Yong, et al.
Publicado: (2022)

Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis
por: Li, He, et al.
Publicado: (2023)

Development of Tumor Mutation Burden-Related Prognostic Model and Novel Biomarker Identification in Stomach Adenocarcinoma
por: Fu, Min, et al.
Publicado: (2022)

Retracted: The Value of m5C-Related lncRNAs in the Prognostic Assessment and Immunotherapy of Stomach Adenocarcinoma
por: International, BioMed Research
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e3mvjggp52vkorfjc7m8824634